NovaBay Pharma (NBY) Reports Q3 Loss of $0.11, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 14, 2018 4:05 PM ESTConference call begins today at 4:30 p.m. Eastern time
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and nine months ended September 30, 2018 and provides a business update.
Net sales for the third quarter of 2018... More



